Amerithroid
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Amerithroid
- Generic name
- THYROID
- Manufacturer
- Oliva Therapeutics, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 03e79049-65b2-4f47-9c98-7ebb324cbc14
- SPL ID
- 15d44dfd-e076-49df-89ef-ff40772e4b3e
- Version
- 3
- Effective date
- 2026-05-13
- Source export date
- 2026-09-28
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/4bbc9760f647649b787710953d978bd6419e899ba8b90f32c3d972aae43947f8/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:06:32
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | Amerithroid | openfda.brand_name | |
| generic name | THYROID | openfda.generic_name | |
| manufacturer name | Oliva Therapeutics, LLC | openfda.manufacturer_name | |
| ndc | package | 82685-345-01 | openfda.package_ndc |
| ndc | package | 82685-342-01 | openfda.package_ndc |
| ndc | package | 82685-346-01 | openfda.package_ndc |
| ndc | package | 82685-347-01 | openfda.package_ndc |
| ndc | package | 82685-344-01 | openfda.package_ndc |
| ndc | package | 82685-341-01 | openfda.package_ndc |
| ndc | package | 82685-343-01 | openfda.package_ndc |
| ndc | package | 82685-348-01 | openfda.package_ndc |
| ndc | product | 82685-348 | openfda.product_ndc |
| ndc | product | 82685-341 | openfda.product_ndc |
| ndc | product | 82685-344 | openfda.product_ndc |
| ndc | product | 82685-347 | openfda.product_ndc |
| ndc | product | 82685-345 | openfda.product_ndc |
| ndc | product | 82685-342 | openfda.product_ndc |
| ndc | product | 82685-343 | openfda.product_ndc |
| ndc | product | 82685-346 | openfda.product_ndc |
| ndc11 | package | 82685034301 | derived:openfda.package_ndc |
| ndc11 | package | 82685034201 | derived:openfda.package_ndc |
| ndc11 | package | 82685034801 | derived:openfda.package_ndc |
| ndc11 | package | 82685034101 | derived:openfda.package_ndc |
| ndc11 | package | 82685034501 | derived:openfda.package_ndc |
| ndc11 | package | 82685034401 | derived:openfda.package_ndc |
| ndc11 | package | 82685034701 | derived:openfda.package_ndc |
| ndc11 | package | 82685034601 | derived:openfda.package_ndc |
| rxcui | 315235 | openfda.rxcui | |
| rxcui | 2743063 | openfda.rxcui | |
| rxcui | 2743055 | openfda.rxcui | |
| rxcui | 2743057 | openfda.rxcui | |
| rxcui | 2743061 | openfda.rxcui | |
| rxcui | 2743059 | openfda.rxcui | |
| rxcui | 314267 | openfda.rxcui | |
| rxcui | 2743051 | openfda.rxcui | |
| rxcui | 313385 | openfda.rxcui | |
| rxcui | 313391 | openfda.rxcui | |
| rxcui | 198278 | openfda.rxcui | |
| rxcui | 208545 | openfda.rxcui | |
| rxcui | 313387 | openfda.rxcui |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. The use of thyroid hormones in the therapy of obesity, alone or combined with other drugs, is unjustified and has been shown to be ineffective. Neither is their use justified for the treatment of male or female infertility unless this condition is accompanied by hypothyroidism.
warnings table
<table width="100%"><colgroup><col width="100%" align="left" valign="top"/></colgroup><tbody><tr styleCode="First Last"><td align="left">Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.</td></tr></tbody></table>
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Adverse reactions other than those indicative of hyperthyroidism because of therapeutic overdosage, either initially or during the maintenance period, are rare (See OVERDOSAGE ).
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.